Introduction

Acute pulmonary embolism ranges from low-risk disease to high-risk PE with sustained hypotension, shock, or cardiac arrest. The 2026 multi-society guideline stratifies PE into high-risk, intermediate-high-risk, intermediate-low-risk, and low-risk categories.1

Systemic IV thrombolysis is a Class I recommendation for high-risk PE. The standard regimen remains alteplase 100 mg IV over 2 hours, with a cardiac arrest option of 0.6 mg/kg up to 50 mg over 15 minutes. The harder question is what to do with intermediate-high-risk PE, where hemodynamic decompensation may be prevented at the cost of substantially more bleeding.

Key Points

  • High-risk PE: systemic thrombolysis is recommended unless contraindicated.
  • Intermediate-high-risk PE: PEITHO showed less decompensation but much more major bleeding and intracranial hemorrhage, without durable mortality or functional benefit.
  • Reduced-dose alteplase strategies are accumulating evidence, including MOPETT and two 2026 RCTs evaluating ultra-low or individualized dosing.
  • Tenecteplase is off-label for PE but operationally attractive because of single-bolus administration.

Alteplase vs Tenecteplase

ParameterAlteplaseTenecteplase
MechanismRecombinant tissue plasminogen activator; converts plasminogen to plasmin and lyses fibrin within the embolus.Modified tPA variant with higher fibrin specificity, lower PAI-1 inhibition, and longer half-life.
PE dosing100 mg IV over 2 hr for high-risk PE. Cardiac arrest: 0.6 mg/kg up to 50 mg over 15 min. MOPETT half-dose: 50 mg total.Not FDA-approved for PE. PEITHO used weight-based single bolus 30-50 mg. PEITHO-3 is evaluating 50% reduced-dose tenecteplase.
AdministrationInfusion over 2 hours, typically via dedicated line. Hold heparin during infusion; resume when aPTT is below 2 times upper normal.Single IV bolus over 5-10 seconds. Operational advantage during rapid deterioration or transfer.
Bleeding signalFull-dose major bleeding roughly 11-13%; reduced-dose strategies appear safer but need careful selection.PEITHO full-dose tenecteplase increased major bleeding and ICH, especially in older adults.

Clinical Pearl

For PE, thrombolytic selection is not only a pharmacology question. It is a systems question: speed, monitoring, bleeding risk, catheter capability, transfer logistics, and whether a PERT pathway exists.

Key Evidence

StudyDesignPractical Takeaway
MAPPET-32n=256, intermediate-risk PE, alteplase + heparin vs heparin alone.Reduced death or treatment escalation, but no significant 30-day mortality difference.
MOPETT3n=121, moderate PE, half-dose alteplase 50 mg vs anticoagulation alone.Pulmonary hypertension reduction with no major bleeding or ICH in either group; important proof-of-concept for reduced-dose lysis.
PEITHO4n=1,005, intermediate-high-risk PE, tenecteplase + heparin vs placebo + heparin.Less hemodynamic decompensation but more major bleeding and ICH; no mortality benefit.
PEITHO long-term7Follow-up of PEITHO outcomes.No durable mortality, dyspnea, RV function, or CTEPH advantage to offset acute bleeding risk.
Kjaergaard 20269n=210, 20 mg alteplase via ultrasound-assisted catheter vs IV vs heparin.Low-dose thrombolysis reduced thrombus burden; ultrasound-assisted catheter delivery did not outperform IV delivery.
Kallai 202610n=19 feasibility trial, viscoelastometry-guided individualized rtPA dosing.Median rtPA dose 32 mg over 8.5 hr; feasibility signal for individualized lower-dose systemic thrombolysis.

Clinical Decision Points

High-risk PE

Systemic thrombolysis is recommended unless contraindicated. Alteplase 100 mg over 2 hours remains the standard labeled regimen.

Intermediate-high-risk PE

Do not reflexively lyse. Weigh RV dysfunction, biomarker elevation, trajectory, age, bleeding risk, and local PERT/CDT capability.

High bleeding risk

Age over 75, recent surgery, recent stroke, active bleeding, or intracranial pathology should push the team toward alternatives or reduced-dose strategies.

Pharmacist checkpoint

Before lysis, verify risk category, contraindications, actual weight if using tenecteplase, heparin timing, access, blood pressure plan, rescue pathway, and post-lysis anticoagulation restart criteria.

Clinical Conclusions

High-risk PE is the clean indication. Systemic thrombolysis is Class I in the 2026 multi-society guideline when no absolute contraindication exists.

Intermediate-high-risk PE is a trade-off. PEITHO reduced hemodynamic collapse but increased major bleeding and ICH, with no durable survival or functional benefit.

Reduced-dose strategies are the evolving space. MOPETT, Kjaergaard 2026, and Kallai 2026 support the concept, while PEITHO-3 is the key trial to watch for reduced-dose tenecteplase.

Do not treat all submassive PE the same. Bleeding risk, age, PERT resources, and clinical trajectory should drive the final lysis decision.

Full Reference List

  1. Creager MA, Barnes GD, Giri J, et al. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults. Circulation. 2026. PMID: 41712677.
  2. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347(15):1143-1150.
  3. Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M. Moderate pulmonary embolism treated with thrombolysis. Am J Cardiol. 2013;111(2):273-277.
  4. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402-1411.
  5. Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo. J Thromb Haemost. 2014;12(4):459-468.
  6. Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of mortality, major bleeding, and intracranial hemorrhage. JAMA. 2014;311(23):2414-2421.
  7. Sanchez O, Charles-Nelson A, Ageno W, et al. PEITHO Long-Term Follow-Up. JAMA. 2022;327(5):450-451.
  8. Klok FA, Kucher N, Klok F, et al. PEITHO-3 trial design. Eur Respir J. 2024;64(2):2400472.
  9. Kjaergaard J, Bang LE, Sonne-Holm E, et al. Randomized trial of low-dose, ultrasound-assisted thrombolysis or heparin for pulmonary embolism. Cardiovasc Res. 2026;122(4):539-549.
  10. Kallai A, Parkanyi A, Berczi M, et al. Personalised viscoelastometry-guided systemic thrombolysis for acute PE. Intensive Care Med Exp. 2026;14(1):e00903.
  11. Rashedi S, Leyva H, Hamade N, et al. Fibrinolytic Therapy for Thromboembolic Diseases. J Am Coll Cardiol. 2025;86(14):1065-1087.
  12. Yogendrakumar V, Xu Y, Gurvitch R, Campbell B. Tenecteplase: expanding horizons in thrombolytic therapy. Heart. 2026;112(4):191-198.
  13. Tapson VF, Sterling K, Jones N, et al. OPTALYSE PE Trial. JACC Cardiovasc Interv. 2018;11(14):1401-1410.
  14. Kucher N, Boekstegers P, Muller OJ, et al. ULTIMA trial. Circulation. 2014;129(4):479-486.
  15. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for acute pulmonary embolism. Eur Heart J. 2020;41(4):543-603.
Tags: Pulmonary Embolism Thrombolysis Alteplase Tenecteplase Pharmacy Friday Pearls